

[Back to Series Home](#)[View Pharmacist Webcast](#)

Drug Conviction Data in KASPER: What is a Pharmacist to Do?


[Print](#)

Activity Progress:

Faculty



Patricia R. Freeman, RPh, PhD, FAPhA
Associate Professor and Director
Center for the Advancement of Pharmacy Practice
University of Kentucky College of Pharmacy
Lexington, Kentucky



Dana L. Quesinberry, JD, DrPH
Assistant Professor, Health Management and Policy
University of Kentucky College of Public Health
Research Core Director
Kentucky Injury Prevention and Research Center
Lexington, Kentucky

Activity Details

- ▶ Credit Amounts:
 - CPE: 1.50
 - Other: 1.50
- ▶ Cost: **Free**
- ▶ Release: **Jan 15, 2020**
- ▶ Expires: **Jan 14, 2023**
- ▶ Estimated Time to Complete:
1 Hour(s) 30 Minutes
- ▶ Average User Rating:
(10 Ratings)

Needs Statement

Kentucky State Senate Bill 32 (2017) mandated that drug conviction data be made available in KASPER effective July 1, 2018. Education to prescribers and dispensing pharmacists on how to interpret this data in the context of patient care and opioid prescribing/dispensing is needed to prevent unintended consequences.

Target Audience

This activity is designed for pharmacists who dispense controlled substances and any other interested healthcare professionals.

Objectives

Kentucky Senate Bill 32 and Drug Conviction Data in KASPER: What Have We Learned?

Upon completion of this educational activity, participants will be able to:

- ▶ Discuss implications of SB 32 that made drug conviction data available in KASPER effective July 1, 2018
- ▶ Review results of Kentucky prescriber and dispenser survey on intent to use drug conviction data in KASPER
- ▶ Assess current data regarding the use of drug conviction data in KASPER by pharmacists and prescribers

Drug Conviction Data in KASPER: What Does it Mean?

Upon completion of this educational activity, participants will be able to:

- ▶ Describe the types of drug-related charges in Kentucky
- ▶ Review example drug conviction data and describe its content and interpretation
- ▶ Identify limitations of drug conviction data
- ▶ Evaluate nuances of interpreting drug conviction data and legal implications

Drug Conviction Data in KASPER: What Should I Do?

Upon completion of this educational activity, participants will be able to:

- ▶ Discuss the impact of criminal conviction data on pharmacists' attitudes and resulting patient health outcomes
- ▶ Use example vignettes to interpret drug conviction data in the context of patient care

- Identify strategies for making sound decisions when dispensing controlled substances to prevent unintended consequences

Accreditation

CPE



The University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned UAN 0022-0000-20-069-H03-P and will award 1.50 contact hours (0.150 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Statements of participation will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes completing the activity, its accompanying evaluation and/or posttest (score 70% or higher) and requesting credit online at the conclusion of the activity. Credit will be uploaded to CPE Monitor, and participants may print a statement of credit or transcript from their NABP e-profile. The College complies with the Accreditation Standards for Continuing Pharmacy Education.

Other

UK Healthcare CECentral certifies this activity for 1.50 hours of participation.

Faculty Disclosure

No speakers, planners, or content reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgment

This project was supported by Grant No. 2017-PM-BX-K026 (Data-Driven Responses to Prescription Drug Misuse in Kentucky) awarded by the Bureau of Justice Assistance (BJA) to the Kentucky Injury Prevention and Research Center as bona fide agent for the Kentucky Department for Public Health.

The BJA is a component of the Department of Justice's Office of Justice Program, which includes the Bureau of Justice Statistics, the National Institute of Justice, the Office of Juvenile Justice and Delinquency Prevention, the Office of Victims Crime, and the SMART Office.

Viewpoints or opinions in these programs are those of the authors and do not necessarily represent the official position or policies of the US Department of Justice.